The maternal and fetal security after ovarian induction.

doi:10.7504/fk2014120111

Abstract

Abstract:

Abstract: Ovulation dysfuction includes disturbance of follicular development and oocyte eduction obstacle caused by polycystic ovary syndrome,endometriosis and pelvic inflammatory disease.The application of ovulation induction drugs can solve the problem.The development of assisted reproductive technology depends on COH in order to improve the oocytes retrival rate and pregnancy rate .But under super physiological state of the Gn, estrogen and progesterone and ovulation inducing drugs may affect the health of both mother and children , so people pay more attention on the side effects and security of the ovulation induction drugs.

Key words: ovarian induction, controlled ovarian hyperstimulation, assisted reproduction technology, ovarian hyperstimulation syndrome

摘要：

排卵障碍包括多囊卵巢综合征、子宫内膜异位症及盆腔炎等引发的卵泡发育障碍及卵子排出障碍，促排卵药物的应用可以有效地解决排卵障碍所致的不孕。辅助生殖技术的开展也更多地依赖于控制性超促排卵（controlled ovarian hyperstimulation，COH）以提高获卵率及妊娠率。而超生理状态下的促性腺激素（Gn）、雌激素、排卵诱导药物及孕激素可能会影响母儿近期及远期的健康,故促排卵过程中发生的副反应及远期的安全性日益受到关注。

关键词: 排卵诱导, 控制性超促排卵, 辅助生殖技术, 卵巢过度刺激综合征

CLC Number:

R321-33

ZUO Na，WANG Xiu-xia.. The maternal and fetal security after ovarian induction.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2014120111.

左娜，王秀霞. 促排卵治疗的母儿安全性[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2014120111.

References

[1］ Roest J, Mous H, Zeilmaker G. The incidence of major clinical complications in a Dutch transport IVF programme［J］. Hum Reprod Update,1996, 2(4):345-353.

[2］ Farquhar.Ectopic pregnancy［J］.Lancet,2005,366(9485):583-591.

[3］ Clayton HB, Schieve. Ectopic pregnancy risk with assisted reproductive technology procedures［J］. Obstet Gynecol,2006, 107(3):595-604.

[4］ de los Ríos JF, Castañeda.Bilateral ectopic pregnancy［J］. Minim Invasive Gynecol, 2007,14(4):419-427.

[5］ Zhe J,Univ-Sci B.Progress and challenges in the cardiovascular field［J］.Biomed Biotechnol,2014,15(8):750-755.

[6］ Sanner K, Conner P, Bergfeldt K,et al .Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of historical cohort in Sweden［J］. Fertil Steril, 2009, 91(4):1152-1158.

[7］ Siristatidis C, Sergentanis TN, Kanavidis P,et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer–a systematic review and meta-analysis［J］. Hum Reprod Update ,2013, 19(2):105-112.

[8］ Li LL, Zhou J, Qian XJ, et al. Meta-analysis on the possible association between in vitro fertilization and cancer risk［J］. Int J Gynecol Cancer, 2013,23(1):16-24.

[9］何帆. 促排卵治疗与卵巢癌发生风险关系的系统评价［J］.中国循证医学杂志,2012，12(9)：1129-1134.

[10］ Russo IH, Russo J. Hormonal approach to breast cancer prevention［J］. J Cell Biochem,2000,34:1-6.

[11］ Ji J, Forsti A, Sundquist J, et al. Risks of breast, endometrial,and ovarian cancers after twin births［J］. Endocr Relat Cancer,2007,14:703-711.

[12］ Nechuta S, Paneth N, Velie EM. Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature［J］. Cancer Causes Control, 2010,21:967-989.

[13］ Seggers J. Is ovarian hyperstimulation associated with higher blood pressure in 4-year-old IVF offspring? Part I: multivariable regression analysis［J］. Hum Reprod,2014,29(3):502-509.

[14］ Reefhuis MA, Honein LA, Schieve,et al. Use of clomiphene citrate and birth defects, national birth defects prevention study, 1997-2005 ［J］. Hum Reprod,2011, 26 (2):451-457.

[15］ Forman R, Gill S, Moretti M, et al. Fetal safety of letrozole and clomiphene citrate for ovulation induction［J］. Obstet Gynecol Can,2007,29:668-671.

[16］ Shai E, Elizur MD, Tulandi T,et al.Drugs in infertility and fetal safety［J］. Fertil Steril,2008,6(89): 1595-1602.

[17］倪郝.控制性卵巢刺激药物对胎儿安全性评价［J］.国际生殖健康/ 计划生育杂志,2011,30(4):302-304.

[18］ Henningsen AK，Pinborg A，Lidegaard，et al.Perinatal outcome of singleton siblings born after assisted reproductive technology and spontaneous conception:Danish national sibling cohort study［J］.Fertil Steril,2011，95: 959-963．

[19］ Kalra SK，Barnhart KT.In vitro fertilization and adverse childhood outcomes: what we know，where we are going，and how we will get there-a glimpse into what lies behind and beckons ahead［J］． Fertil Steril，2011，95(6): 1887-1889．

[1]	DENG Shan, TIAN Qin-jie. Endometrial polyps and fertility. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(3): 273-276.
[2]	YUAN Yuan，ZHOU Can-quan. Clinical approaches to poor ovarian responders in assisted reproductive technology. [J]. Acta Metallurgica Sinica, 2017, 33(1): 81-85.
[3]	HU Xiao-kun，XU Yan-wen.. Selection of ovarian stimulation protocols and characteristics analysis of preimplantation genetic diagnosis cycles. [J]. Acta Metallurgica Sinica, 2016, 32(2): 237-240.
[4]	MA Cai-hong,WANG Yang.. The complications of ovulation induction and its prevention. [J]. Acta Metallurgica Sinica, 2015, 31(1): 39-43.
[5]	ZHENG Xiao-ying,WANG Hai-yan.. Assisted reproductive technology and AIDS. [J]. Acta Metallurgica Sinica, 2014, 30(9): 679-681.